AFT PHARMACEUTICALS LIMITED |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2.85 NZD | +0.35% |
|
-1.72% | -18.57% |
| May. 01 | AFT Pharmaceuticals Signs Brazil Licensing Agreement for Maxigesic IV | MT |
| Apr. 24 | New Zealand Shares Rise on US Earnings Rally; AFT Pharmaceuticals to Develop Topical Scar Treatment | MT |
Presenter SpeechDavid Flacks (Executives)[Foreign Language] And good morning, and welcome to A...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
AFT Pharmaceuticals Limited is a New Zealand-based multinational pharmaceutical company. The Company develops, markets and distributes a portfolio of pharmaceutical products across a range of therapeutic categories, which are distributed across three pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Its product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. The Company develops and in-licenses products for sale by its own dedicated sales teams in Australia and New Zealand and in certain Southeast Asian markets, and out-licenses its products to local licensees and distributors in the rest of the world. A-Scabies, Allersoothe, Allersoothe Elixir, BecloClear, Bites, Calci-Tab, Candacort, Candacort Minipak, Candaderm, Coco-Scalp, Combolieve, Cromo-Fresh, Dry skin, Eczema, Emulsifying Ointment BP, Fenpaed, Fenpaed Double Strength, Ferro-Sachets, HYLO-FORTE and others.
Sector
Pharmaceuticals
Calendar
2024-05-22
- Q4 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.84
NZD
Average target price
3.7
NZD
Spread / Average Target
+30.28%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -18.57% | 182M | |
| +32.04% | 694B | |
| +29.39% | 593B | |
| -1.77% | 371B | |
| +20.01% | 331B | |
| +6.94% | 290B | |
| +14.25% | 239B | |
| -3.03% | 209B | |
| +10.02% | 209B | |
| +7.99% | 169B |
- Stock Market
- Equities
- AFT Stock
- News AFT Pharmaceuticals Limited
- Transcript : AFT Pharmaceuticals Limited - Shareholder/Analyst Call